Cancer Research UK, Abcam partner on cancer antibodies

By The Science Advisory Board staff writers

July 8, 2020 -- Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used to further understand cancer biology, create new diagnostic tools, and potentially develop novel therapies.

Under the terms of the agreement, the Cancer UK-funded researchers can request Abcam to supply antibodies developed from the partnership for an agreed period of exclusivity. After the unspecified period of exclusivity ends, Abcam will utilize its supply capability to make the antibodies available to the wider research and diagnostic development community.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.